Kawasumi Laboratories Inc. announced consolidated earnings results for the nine months ended December 31, 2016. For the period, the company reported net sales of ¥18,404 million, operating income of ¥802 million, ordinary income of ¥916 million, profit attributable to owners of the parent of ¥979 million or net income per share of ¥44.90 compared to net sales of ¥21,137 million, operating income of ¥1,594 million, ordinary income of ¥1,700 million, net income of ¥1,240 million or net income per share of ¥54.24 for the same period last year. Profit before income taxes was ¥937 million against ¥1,716 million a year ago. Net cash provided by operating activities was ¥1,805 million against ¥1,834 million a year ago. Purchase of property, plant and equipment was ¥850 million against ¥278 million a year ago. Purchase of intangible assets was ¥230 million against ¥26 million a year ago.

The company provided dividend guidance for the year end of fiscal year ending March 31, 2017. For the period, the company expects dividend of ¥7.50 per share against ¥7.50 per share a year ago.

For the full year of fiscal year ending March 31, 2017, the company expects consolidated net sales of ¥25,700 million, operating income of ¥1,150 million, ordinary income of ¥1,150 million, profit attributable to owners of the parent of ¥1,200 million or net income per share of ¥55.01.